Edward M. Md Kaye Stoke Therapeutics, Inc. (STOK) insider trading activity

Edward M. Md Kaye is CEO of Stoke Therapeutics, Inc.. Currently has a direct ownership of 96,885 shares of STOK, which is worth approximately $846,774. The most recent transaction as insider was on Dec 30, 2024, when has been sold 35,000 shares (Common Stock) at a price of $0.6 per share, resulting in proceeds of $21,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 96.9K

258.83% 3M change

115.3% 12M change

Total Value Held $846,774

Edward M. MD Kaye Transaction History

Date	Transaction	Value	Shares Traded	Shares Held	Form
Date	Transaction	Value	Shares Traded	Shares Held	Form
Dec 30 2024	BUY Exercise of conversion of derivative security	$21,000 $0.6 p/Share	35,000 Added 26.54%	96,885 Common Stock
Dec 09 2024	SELL Open market or private sale	$88,150 $12.99 p/Share	6,786 Reduced 9.88%	61,885 Common Stock
Dec 06 2024	SELL Open market or private sale	$78,852 $12.78 p/Share	6,170 Reduced 8.24%	68,671 Common Stock
Dec 03 2024	BUY Exercise of conversion of derivative security	-	26,500 Added 26.08%	75,091 Common Stock
Dec 01 2024	BUY Exercise of conversion of derivative security	-	21,591 Added 30.76%	48,591 Common Stock
May 20 2024	SELL Open market or private sale	$665,742 $15.72 p/Share	42,350 Reduced 61.07%	27,000 Common Stock
Mar 19 2024	SELL Open market or private sale	$68,015 $6.1 p/Share	11,150 Reduced 13.85%	69,350 Common Stock
Mar 15 2024	BUY Exercise of conversion of derivative security	-	35,500 Added 30.6%	80,500 Common Stock
Mar 27 2023	BUY Exercise of conversion of derivative security	$12,000 $0.6 p/Share	20,000 Added 30.77%	45,000 Common Stock
May 25 2022	BUY Exercise of conversion of derivative security	$9,000 $0.6 p/Share	15,000 Added 37.5%	25,000 Common Stock
Dec 30 2020	BUY Exercise of conversion of derivative security	$6,000 $0.6 p/Share	10,000 Added 50.0%	10,000 Common Stock
Dec 18 2020	SELL Open market or private sale	$311,640 $60.0 p/Share	5,194 Reduced 100.0%	0 Common Stock
Dec 17 2020	SELL Open market or private sale	$1,188,360 $60.0 p/Share	19,806 Reduced 79.22%	5,194 Common Stock
Nov 27 2020	SELL Open market or private sale	$607,600 $50.0 p/Share	12,152 Reduced 32.71%	25,000 Common Stock
Nov 25 2020	SELL Open market or private sale	$642,400 $50.0 p/Share	12,848 Reduced 25.7%	37,152 Common Stock

Also insider at

CYTK

CYTOKINETICS INC Healthcare

Director

RNA

Avidity Biosciences, Inc. Healthcare

Director

EMM

Edward M. Md Kaye

CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells STOK shares.

Notify only if

Value

Any

Insider Trading

Get notified when an Stoke Therapeutics, Inc. insider buys or sells STOK shares.

Notify only if

Operation

Any

Value

Any

Type

P - Open market or private purchase×

S - Open market or private sale×

V - Transaction voluntarily reported earlier than required×

A - Grant, award, or other acquisition×

D - Sale (or disposition) back to the issuer×

F - Payment of exercise price or tax liability×

I - Discretionary transaction×

M - Exercise of conversion of derivative security×

C - Conversion of derivative security×

E - Expiration of short derivative position×

H - Expiration (or cancellation) of long derivative position with value received×

O - Exercise of out-of-the-money derivative securities×

X - Exercise of in-the-money or at-the-money derivatives securities×

G - Bona fide gift×

L - Small Acquisition×

W - Acquisition or disposition by will or laws×

Z - Deposit into or withdrawal from voting trust×

J - Other acquisition or disposition×

K - Transaction in equity swap or similar instrument×

U - Disposition due to a tender of shares in a change of control transaction×

20 item(s) selected

News

Receive news related to Stoke Therapeutics, Inc.

Track Activities on STOK

Account